MURAL ONCOLOGY, INC.

Mural Oncology's virtual Investor Day highlights late-stage clinical progress of nemvaleukin, with key data readouts expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma. The company also plans to submit an IND for its IL-18 program in Q4 2025.

ARTISTRY-6 cohort 2 is a registrational study of nemvaleukin in unresectable or metastatic mucosal melanoma. Primary endpoint is overall response rate, with secondary endpoints including duration of response and safety. Nemvaleukin has FDA Fast Track and Orphan Drug designations. Enrollment complete with 92 patients. Target response rate is 25%, with a meaningful response rate of 20-25% supporting potential BLA submission. Primary analysis at six months follow-up, with top-line readout expected in Q2 2025. Potential accelerated approval contingent on confirmatory evidence.